Pages that link to "Q72421111"

The following pages link to Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function (Q72421111):

Displaying 44 items.

• Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy (Q28372859) (← links)
• First-pass elimination. Basic concepts and clinical consequences (Q34257205) (← links)
• Influence of acid secretory status on absorption of omeprazole from enteric coated granules (Q34358008) (← links)
• The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol (Q34511658) (← links)
• Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man (Q34622407) (← links)
• Drug Prescribing in Renal Failure: Dosing Guidelines for Adults (Q34708717) (← links)
• Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease (Q35316627) (← links)
• Beta blockers in the management of chronic kidney disease (Q36614867) (← links)
• The Effect of Renal Failure on Hepatic Drug Clearance (Q36884131) (← links)
• Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications (Q36923315) (← links)
• Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine (Q39239760) (← links)
• Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension (Q39263312) (← links)
• Plasma levels and β-blocking effect of α-hydroxymetoprolol—Metabolite of metoprolol—in the dog (Q39297603) (← links)
• Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update (Q39463386) (← links)
• The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction (Q39465367) (← links)
• Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders (Q39478484) (← links)
• Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. (Q40072776) (← links)
• Pharmacokinetic aspects of some β-adrenoceptor blocking drugs (Q40089241) (← links)
• Drug metabolites in renal failure: pharmacokinetic and clinical implications (Q40325635) (← links)
• Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol (Q40923122) (← links)
• Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy (Q41002347) (← links)
• Defective metabolism of metoprolol in poor hydroxylators of debrisoquine (Q41760769) (← links)
• Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing (Q42639468) (← links)
• Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study (Q43724215) (← links)
• The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction (Q44476289) (← links)
• Inter- and intra-subject variability of metoprolol kinetics after intravenous administration. (Q52379468) (← links)
• β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. (Q53838798) (← links)
• Influence of smoking and gender on the disposition kinetics of metoprolol (Q68687377) (← links)
• Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease (Q69904141) (← links)
• Determination of metoprolol and alpha-hydroxymetoprolol in plasma by high-performance liquid chromatography (Q70340333) (← links)
• The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol (Q70788231) (← links)
• Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards (Q70936740) (← links)
• Pharmacokinetics of Metoprolol in Patients with Hepatic Cirrhosis (Q71082671) (← links)
• The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites (Q71156663) (← links)
• The pharmacokinetics of metoprolol and its metabolites in dialysis patients (Q71156668) (← links)
• Determination of metoprolol in human blood plasma using high-performance liquid chromatography (Q71169306) (← links)
• Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals (Q71705871) (← links)
• Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents (Q72430108) (← links)
• High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (Q72520072) (← links)
• Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man (Q72593006) (← links)
• Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat (Q74072095) (← links)
• Formulation and evaluation of controlled release Eudragit buccal patches (Q77331740) (← links)
• A Refined Developability Classification System (Q88388194) (← links)
• Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and β-blockers - drug classes with low adherence in antihypertensive therapy (Q91012384) (← links)